NSCLC: FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease

Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adult patients with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.

Metabolic Syndrome Frequently Documented During First Year of ADT-ARPI Therapy in Prostate Cancer

Metabolic abnormalities were frequently documented during the first year after men with prostate cancer began concurrent androgen-deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI), according to a large retrospective cohort study.

Refined Risk Index Improves Outcome Prediction After Limited-Duration CLL Therapy

Researchers developed a dynamic risk model integrating longitudinal measurable residual disease assessments to explore whether prognosis can be more precisely defined for patients with chronic lymphocytic leukemia (CLL) following limited-duration therapy.

NEWS FROM ASCO AI IN ONCOLOGY Is Federated Learning the Answer to Patient Privacy in AI? Watch This Webinar Tonight at 6 PM EST—Register Now